FDA pulls U.S. authorization for Eli Lilly's COVID drug bebtelovimab

The Hill

Center

High Factuality

Media Conglomerate: Nexstar Media Group

FDA pauses authorization for last remaining COVID-19 monoclonal antibody treatment

The Food and Drug Administration (FDA) said on Wednesday that the COVID-19 monoclonal antibody treatment bebtelovimab from Eli Lilly is no longer authorized for emergency use in the U.S. as it is not expected to be effective at neutralizing the two most dominant omicron subvariants in the country right now. The omicron subvariants BQ.1 and…

Bloomberg

Lean Left

Mixed Factuality

Individual: Michael Bloomberg

Private Equity: The Vanguard Group

FDA pulls U.S. authorization for Eli Lilly's COVID drug bebtelovimab

The Globe & Mail

Center

High Factuality

Private Equity: The Woodbridge Company

Setback for B.C.’s AbCellera as FDA pulls U.S. authorization for its COVID-19 antibody

Bebtelovimab, developed in partnership with Eli Lilly, got emergency okay for sale in February

Wall Street Journal

Center

High Factuality

Media Conglomerate: Murdoch Family

FDA Pulls Lilly’s Covid Antibody Drug

The drug bebtelovimab isn’t expected to neutralize now-common Omicron subvariants BQ. 1 and BQ. 1.1

Investing.com

Center

Mixed Factuality

FDA pulls U.S. authorization for Eli Lilly's COVID drug bebtelovimab By Reuters

FDA pulls U.S. authorization for Eli Lilly's COVID drug bebtelovimab